Cytek Biosciences Q1 revenue rises 6%, slightly misses estimates

Cytek Biosciences

07/05/2026 21:51

Overview

Cell analysis solutions provider's Q1 revenue rose 6% yr/yr, slightly missing analyst expectations

Company posted Q1 net loss of $18.9 mln, with adjusted EBITDA loss widening yr/yr

Cytek reaffirmed 2026 revenue guidance of $205 mln to $212 mln, up 2%-5% over 2025

Outlook

Cytek Biosciences reaffirms 2026 revenue guidance of $205 mln to $212 mln

Company expects 2026 revenue growth of 2% to 5% over 2025

2026 guidance assumes no change from current currency exchange rates

Result Drivers

RECURRING REVENUE - Growth in service and reagent revenue contributed to higher total and recurring revenue, per company

INSTALLED BASE EXPANSION - Addition of 125 instruments in Q1 expanded installed base, supporting demand for reagents and service,

HIGHER ADMINISTRATIVE COSTS - General and administrative expenses rose 43% yr/yr due primarily to litigation-related expenses, outside consulting expenses and bad debt reserves

Company press release: ID:nGNXbwy8zJ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Miss*
$44.14 mln
$44.33 mln (3 Analysts)
Q1 Net Income
-$18.87 mln
Q1 Adjusted EBITDA
-$9.07 mln
Q1 Adjusted Gross Margin
51.00%
Q1 Pretax Profit
-$17.37 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cytek Biosciences Inc is $5.75, about 16.4% above its May 6 closing price of $4.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)